Why the study?
Does carvedilol reduce all-cause mortality in adults with systolic heart failure and chronic kidney disease?
Does carvedilol reduce all-cause mortality in adults with systolic heart failure and chronic kidney disease?
Carvedilol significantly reduces all-cause mortality and heart failure hospitalizations in patients with systolic heart failure and mild to moderate chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Supports carvedilol in systolic HF with CKD to reduce mortality; extends evidence to this high-risk subgroup.
Wali et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: